The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
 
Jie Liu
Speakers' Bureau - Eisai; MSD; Novartis; Roche; Shanghai Junshi BioSciences
 
Yaotiao Deng
Speakers' Bureau - Chia Tai Tianqing Pharmaceutical Group; Eisai Europe; MSD; Novartis; Roche; Shanghai Junshi BioSciences; Shenzhen Chipscreen Biosciences
 
Ying Wang
Speakers' Bureau - MSD, Roche, Novartis, Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd
 
Jie Zhang
Speakers' Bureau - MSD, Roche, Novartis, Eli Lilly Nederland B.V.,Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd
 
Mei Li
Speakers' Bureau - MSD, Roche, Novartis, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd
 
Yu Jiang
Speakers' Bureau - Eisai Europe; MSD; Novartis; Roche; Shanghai Junshi BioSciences